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1 Introduction
Plasmodium falciparum sporozoite invasion is 
inhibited by naturally acquired or experimentally 
induced polyclonal antibodies to the STARP 
antigen
Antibody(Ab)-mediated inhibition of sporozoite invasion of hepatocytes is a 
mechanism that has been clearly demonstrated to act upon Plasmodium falcipa­
rum pre-erythrocytic stages in humans. Consequently we have analyzed the Ab 
response to a recently identified P. falciparum sporozoite surface protein, 
STARP, in malaria-exposed individuals and tested the inhibitory effect of these 
Ab upon hepatocyte invasion in vitro. STARP-specific IgG were detected in 90 
and 61 % of sera from regions where individuals were exposed to 100 and 1-5 
infectious bites per year, respectively. These IgG were predominantly of the 
cytophilic IgGl or IgG3 type. STARP and the major sporozoite surface protein, 
CS, elicited equivalent IgG levels in adults. When affinity purified from either 
African immune sera or the serum of an individual experimentally protected by 
irradiated sporozoite immunization, STARP-specific Ab prevented up to 90% 
of sporozoites from invading human hepatocytes. The dose-dependent and 
reproducible inhibition was more pronounced than that observed with human 
CS-specific Ab affinity purified under identical conditions. Substantial reduction 
of sporozoite invasion was also observed with Ab induced by artificial immuniza­
tion with recombinant STARP protein and reactive with the native protein. 
Taken together with recent findings of human cytotoxic T lymphocytes specific 
for this antigen, these results promote the interest of studying the efficacy of 
STARP as a target for immune effector mechanisms operating upon pre- 
erythrocytic stages.
Malaria caused by the protozoan parasite Plasmodium fal­
ciparum represents a major cause of morbidity and mortal­
ity in many tropical areas in the world and is therefore the 
focus of efforts aimed at artificially inducing an effective 
immunity. Experimentally, it has been reproducibly shown 
that sterile, stage-specific immunity can be acquired in 
humans immunized with P. falciparum irradiation- 
attenuated sporozoites (IrrSpz) [1-4]. Therefore, a major 
goal has become the identification of the critical effector 
mechanism(s) and Ag responsible, with the aim of devel­
oping a recombinant vaccine against pre-erythrocytic 
stages [sporozoites (Spz) and/or liver stages (LS)].
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Work conducted mainly in rodent malaria models has 
uncovered a plethora of Ab- and cell-mediated immune 
mechanisms operating upon malaria pre-erythrocytic 
stages, including Ab acting upon Spz and CTL, cytokines 
and free radicals targeting infected hepatocytes (reviewed 
in [5-7]). While the critical effector role of CD8+ or CD4‘ 
CTL operating on the liver stages has been clearly 
demonstrated for certain rodent malaria systems such as 
BALB/c-Plasmodium yoelii or A/J-Plasmodium berghei 
[8-10], in other combinations such as B10.BR-f! yoelii or 
BALB/c-i? berghei, these have been shown to have little if 
any effect [11]. Non-stimulated human hepatocytes do not 
express detectable levels of MHC class I or class II mole­
cules, although MHC class II expression can be induced 
by IFN-y [12, 13]; indeed human liver transplants are rou­
tinely performed using non-MHC-matched donors. Thus, 
in the absence of evidence demonstrating whether P. 
falciparum-infected human hepatocytes are indeed up- 
regulated in their MHC gene expression, caution must be 
exercised in extrapolating rodent malaria data to the 
human context. One mechanism, however, which has been 
clearly demonstrated for P. falciparum is that of Ab- 
mediated inhibition of Spz invasion of human hepatocytes 
[14-16]. Moreover, comparisons of P. falciparum and P. 
yoelii in vitro and in vivo suggest that the “Inhibition of 
Liver-Stage Development Assay” (ILSDA), which 
employs the natural host cell, the hepatocyte, can be pre­
dictive of the effect in vivo of the Ab tested [15, 17, 18].
In terms of the critical target P. falciparum Ag, for many 
years the focus was exclusively on the major Spz surface 
protein, the CS. However, CS vaccine trials conducted in 
endemic areas have yet to show that protective immunity 
comparable to the IrrSpz vaccines can be induced [19].
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While more immunogenic experimental CS vaccines look 
promising, there are several arguments in favor of analyz­
ing additional pre-erythrocytic stage antigens. First, there 
is documented immunological non-responsiveness and 
antigenic diversity within T cell epitopes of the CS protein 
(reviewed in [20]). Second, the presence of CTL and Ab to 
the CS protein is not indicative of protective immunity 
induced in humans or mice by immunization with IrrSpz 
([21] and references within). Third, experiments with P. 
yoelii have indicated that combining additional pre- 
erythrocytic stage Ag with the CS protein give far broader 
protection than was possible with the CS alone [21, 22]. 
Last, it is now clear that the CS is only one of many Ag 
present in P. falciparum, pre-erythrocytic stages [5, 23, 24]. 
Of these, the recently discovered STARP Ag has the 
attractive property of being found on the surface of all Spz 
strains and isolates tested to date (using Ab directed to the 
repeats of a single parasite clone) as well as being detected 
at high levels in liver stages [25], Expression of this gene in 
sporozoites has been conclusively demonstrated by North­
ern (RNA) blot and reverse transcriptase PCR. The 78- 
kDa STARP protein contains three internal repeat regi­
ons, denoted Mosaic (containing multiple small degener­
ate repeats), Rp45 and RplO (encoding 45- and 10-amino 
acid repeats, respectively); this structure is highly con­
served in P falciparum [26]. Recently, the STARP Ag was 
found to contain an HLA-A*0202-restricted epitope for 
CTL in humans naturally exposed to malaria infection 
[27], suggesting that it may be a target of cell-mediated 
immune mechanisms operating upon infected hepatocytes. 
Subsequently, 75 % of individuals from a high- 
transmission region were found to have a CTL response to 
this epitope, exceeding the frequency of response to all 
other CTL epitopes studied from other P falciparum pre- 
erythrocytic stage Ag [28].
Consistent localization of STARP at the Spz surface [25] 
also raises the possibility that this Ag may constitute an 
effective target for Ab capable of preventing Spz invasion 
of hepatocytes. This question has been addressed by exam­
ining Ab responses to STARP in the serum of malaria- 
exposed individuals and assessing the capacity of these Ab 
to inhibit P. falciparum Spz invasion of human hepato­
cytes, using the ILSDA in vitro assay. Results show a 
strong biological effect of both STARP-specific Ab puri­
fied from the sera of either African individuals exposed to 
P. falciparum malaria or an individual experimentally pro­
tected by immunization with IrrSpz, and Ab produced in 
animals immunized with the recombinant protein.
2 Materials and methods
2.1 Sero-epidemiological study areas and serum donors
Donse is a rural village of 500 inhabitants situated 50 km 
north of the capital in a Savannah area of Burkina Faso. 
Malaria there is seasonal with parasite transmission rates 
averaging 100 infectious bites per individual per year [29]. 
Podor (Northern Senegal), situated 10 km south of the 
Senegal river, is a dry Sahel area with a brief transmission 
season characterized by only one to five infectious bites 
per individual per year [30] which is low by African stan­
dards. After informed consent, plasma samples were 
obtained from donors whose age ranged from 1 to 75
years. Sample groups for serological studies were chosen 
to have an even distribution over the different age groups 
studied.
Recently, the immunity which can be induced by immu­
nization with IrrSpz was re-assessed in a group of four 
volunteers [4, 31]. For the purpose of our study, a large 
volume of serum was very kindly donated by one of these 
volunteers (referred to as WR4 in [4] and 5H in [31]; in this 
study as IS-VoI). This volunteer had been repeatedly 
immunized by IrrSpz and was protected against multiple 
challenges by both homologous and heterologous P. falci­
parum strains.
2.2 STARP peptide selection and design of the mixotope
On the basis of preliminary serological studies using vari­
ous STARP recombinants, which localized immunodomi­
nant B cell epitopes to the RplO region (D. Fidock, unpub­
lished data), this region was chosen to characterize and 
evaluate STARP-specific Ab responses. The 10-amino acid 
encoding RplO region alone accounts for 40 % of the 
entire STARP sequence. The localization of immunodom­
inant epitopes to this region agrees with previous reports 
that repetitive regions of P falciparum antigens frequently 
contain immunodominant Bcell epitopes [32, 33]. From 
the RplO region we designed two peptide Ag, i.e. RplO-A 
and a convergent, combinatorial, multi-epitope peptide, 
the mixotope RplO-Mixo (Table 1).
2.3 Peptide synthesis and recombinant antigens
The synthesis of both STARP peptides was performed on 
a Na-Boc NE palmitoyl lysine-MBHA. The C-terminal 
lysine was introduced on the MBHA resin (0.5 mmol; 
loading of the starting resin at 0.55 mmol/g) as Na-Boc, NE 
Fmoc lysine. After piperidine deprotection of the Fmoc 
group, the Ne function was palmitoylated using palmitic 
acid activated with dicyclohexylcarbodiimide/l-hydro- 
xybenzol-triazole (DCC/HOBt). The synthesis of RplO-A 
was performed in an automatic peptide synthesizer 
(Applied Biosystems model 430 A, Foster City, CA) using 
the conventional N-tert-Butoxy-carbonyl-trifluoro-acetic 
acid (BOC-TFA) strategy and a DCC-HOBt activation 
method [34], After assembly of the complete protected 
peptide chain, the terminal t-BOC group was removed 
with 50% TFA. Following neutralization, the N-terminal 
group was then acetylated using acetic anhydride. The 
resin was dried, cleaved and deprotected in HF, r-cresol
and thiocresol (90.0:7.5:2.5) for 2 h at 0°C. Initially, the 
crude peptide was dissolved in 30 ml neat TFA, then preci­
pitated by pouring this into 300 ml dry ice-cooled diethyle- 
ther. This peptide was found to be totally water-insoluble. 
Thus, to prevent aggregation, 100 mg crude peptide was 
solubilized with TFA in the presence of 600 mg SDS [35]. 
This product, when precipitated with ether, could then be 
solubilized with water. Excess SDS was eliminated by 
extensive dialysis.
The synthesis of the mixotope RplO-Mixo was performed 
on 0.5 mmol of Na-Boc, Ne palmitoyl lysine-MBHA as 
described [36]. Precise equimolecular amounts of appro­
priate protected amino acids were used in coupling reac-
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Table 1. STARP RplO region - amino acid distribution and syn­
thetic peptides
RplO
regiona)
1 2 3 4 5 6 7 8 9 10
Sl4 T23 D25 N25 N14 N23 T21 Nio T18 112
L5 U Tl si S3 K2 12 D6 14 K8
A4 Nl T3 Si A2 K6 V2 N3
El n D3 Nl T3 Kl t 2
Pi 11 Gl Ql VI
Tl Kl
n
RplO-Ab) STDNNNTKTISTDNNNTKTI- (pam)K-COOH
RplO-Mixoc) STDNNNTNTISTDNNNTNTI-(pam)K-COOH 
L T NTIKA S IT N 
D D NL D T
K K K
a) The STARP Rp'10 (10-amino acid repeat) region is composed 
of 26 repeat units that show considerable sequence diversity 
[25]. These units were aligned vertically and for each position 
(1 -10) we have listed the amino acids utilized and the number 
of times that each amino acid was present, in order of decreas­
ing use. The top row indicates the most frequently used amino 
acids.
b) RplO-A is a synthetic linear 20-mer peptide representing two 
copies of the only repeat unit present more than once in this 
region (as three tandem copies in the T9/96 clone [25],
c) RplO-Mixo is a convergent combinatorial peptide designed 
from the RplO region following alignment of the sequence as a 
string of 20 amino acids. In RplO-Mixo, any residues found at 
least twice at a given position in the repeat sequence string 
were incorporated in that position during synthesis. Equimolar 
amounts of the appropriate subset of amino acids (shown vert­
ically) were introduced in each degenerate position. This the­
oretically produced 55 296 closely related combinatorial 
sequences, collectively representing not only the observed 
degeneracy in the RplO repeats [25], but indeed all possible 
RplO sequences that the parasite could generate using this set 
of amino acids.
tions when degenerated sites were required. The first 
coupling was performed with 0.5 nmol total amount of the 
introduced BOC amino acids. A second coupling, using
2 mmol total amount, was then systematically performed. 
The activation procedure was the DCC/HOBt method, 
with long coupling reaction (90 min) periods. The com­
pleteness of the coupling reaction was tested by a qual­
itative ninhydrin assay and a third coupling performed 
when necessary. After synthesis, the resin was dried, 
cleaved and deprotected in HF, r-cresol and thiocresol 
(90.0:7.5:2*5) for 2 h at 0 °C. The cleaved deprotected pep­
tide was precipitated, extensively washed with cold diethyl- 
ether, dissolved in 5% acetic acid and lyophilized. Final 
amino acid compositions, determined 24 h and 48 h after 
acid hydrolysis, accurately reflected the theoretical com­
position, calculated on the basis of an equimolecular 
amount of each amino acid introduced in the degenerated 
positions.
The LSA-Rep peptide, previously described [37], repre­
sents 2.5 units of the 17-amino acid immunodominant 
repeat of the liver stage Ag LSA-1. The CS peptide
(NANP)ö was purchased from Bachem (Bubendorf, Swit­
zerland). The CS peptide [(NANP)r NVDP]2 was a kind 
gift of the late R. L. Beaudoin. The R32tet32 recombinant 
protein ([(NANP)l5NVDP)]2-tet32) was an aliquot of the 
highly purified CS protein described in [38], a kind gift of 
Mitch Gross (SmithKline Beecham).
2.4 ELISA assays
These were performed essentially as described in [39]. 
Briefly, peptides RplO-A or RplO-Mixo were coated onto 
ELISA plates (Nunc-Immuno Plate II, Nunc) overnight at 
4°C (100 pi/well of a 10 solution in 50 mM Na2C 03, 
pH 9.5). Sample sera, tested in duplicate, were diluted 
either 1:100 for IgG detection or 1:25 for isotype studies 
(detection of IgGl-4, IgA and IgM). Bound IgG or IgA 
were quantified using peroxidase-conjugated goat anti­
human IgG or IgA, respectively (1:2000 dilution; Biosys, 
Compiegne, France). IgGl-4 isotypes were detected using 
anti-human isotype-specific mAb followed by peroxidase- 
labeled goat anti-mouse IgG (1:1000 dilution; Biosys) as 
described [40]. These mAb had been previously selected 
for their ability to recognize equally well the correspond­
ing isotype in sera from Caucasians, Africans or Asians 
and were employed at empirically determined concentra­
tions that gave isotype-specific results and similar absor­
bance readings for each subclass. The mAb employed 
were: mouse anti-IgGl (NL16, diluted 1:20000; Boehrin- 
ger Mannheim); -IgG2 (HP6002, diluted 1:10000; 
Sigma); -IgG3 (ZG4, diluted 1:10000; Immunotech); 
-IgG4 (RJ4, diluted 1:1000; Immunotech); and -IgM 
(MB 11, diluted 1:30000; Sigma).
Prior to conducting the sero-epidemiological assays, each 
peptide was initially tested on a control group of 80 serum 
samples from healthy French blood donors with no history 
of malaria exposure. Five serum samples reproducing the 
mean and standard deviation of the control group were 
selected and included on each subsequent assay plate, 
along with two positive control African adult sera.
Antibody levels of test serum were defined in arbitrary 
units (AU), where the number of AU was calculated by 
dividing the mean absorbance (OD492) value of the test 
serum by the mean + 3 SD of the five control serum sam­
ples from the same plate. AU values > 1 were considered 
as indicative of the presence of specific Ab, This definition 
is the more stringent of the two commonly employed in 
malaria sero-epidemiology studies for defining a positive 
Ab response [37, 41, 42], the other one using 2 SD instead 
of 3 SD in the formula shown above [43, 44]. Use of 
exactly the same definition, sera samples and protocol 
enabled comparison of these results with our previously 
published data on the LSA-1 and CS Ag [37],
2.5 Affinity purification of human specific antibodies
Specific human antibodies were prepared from immune 
serum by affinity purification using ELISA plate-bound 
synthetic peptides or purified recombinant R32tet32 pro­
tein bound to ELISA plates, as described in [37], Briefly, 
peptides or protein were coated onto ELISA plates by 
overnight incubation at 4°C (200 i^l/well of 10 |xg/ml solu­
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tions). After washing, wells were incubated for 1 h at 22 °C 
with human immune serum (diluted 1 : 100; 200 [il/well). 
Following extensive washes, Ag-bound Ab were eluted 
using 0.2 M glycine, pH 2.5 and immediately neutralized 
by the addition of 2 M Tris, pH 11. Eluted Ab samples 
were dialyzed extensively first against PBS, pH 7.4, then 
William’s E culture medium (Gibco BRL). Samples were 
concentrated over a Centricon 30 (Amicon) membrane 
and protein concentrations calculated using a Bradford 
protein assay (Bio-Rad). The purity and concentrations of 
specific Ig in eluted Ab samples were estimated by scan­
ning known amounts of stained PAGE Ig preparations 
with a laser densitometer (LKB Bromma Ultroscan XL). 
Samples were adjusted to final working concentrations in 
freshly supplemented William’s E medium and filter steril­
ized (0.22 |xm Millex filters, Millipore, Bedford, MA).The 
specificity of the Ab preparations for the STARP Ag was 
verified by ELISA on STARP peptides, by immunofluo- 
rescent antibody test (IFAT) on P falciparum Spz, reveal­
ing the characteristic heterogeneous STARP Spz surface 
staining [25], and by immunoblot analysis of cultured asex­
ual early ring forms (which express STARP). Affinity- 
purified anti-STARP Ab were never found to cross-react 
with the CS Ag, nor were anti-CS Ab found to cross-react 
with STARP.
2.6 Mouse antisera
Polyclonal anti-STARP antisera were obtained from Swiss 
outbred mice (Charles River, France) immunized by three 
injections at 2-week intervals of 15 t^g of the entire repeat 
region of the STARP Ag (amino acids 81-528, T9/96 clone) 
expressed and purified as a glutathione-S-transferase 
(GST) fusion protein (referred to as GST+STARP/Rep), 
as described [25].
2.7 IgG preparations
IgG was purified from eluted human Ab or polyclonal 
mouse antisera by ion exchange chromatography on 
DEAE-Trisacryl (IBF, Biotechnics, Villeneuve-la-Ga­
renne, France), according to the manufacturer’s specifica­
tions. This procedure, which is used to separate IgG 
(eluted with 35 mM NaCl, 25 mMTris, pH 8 .8) from IgM 
and IgA (eluted with 500 mM NaCl, 25 mMTris, pH 8 .8), 
was later found to efficiently purify IgGl, 2 and 3, and to 
leave contaminating IgG4 in the IgM and A fraction. The 
effective separation of the Ig (sub)classes was verified in 
dot blot and ELISA assays using (sub)class-specific sec­
ondary Ab. Prior to use in the in vitro assays, Ig samples 
were first dialyzed against supplemented William’s E 
medium, then adjusted to the final working concentrations 
and filter-sterilized as described above. The Ab activity of 
the recovered fractions was ascertained by testing serial 
sample dilutions in IFAT assays on R falciparum Spz and 
by ELISA assays.
2.8 Immunofluorescent antibody tests
The presence and titer of purified Ab specific to P falcipa­
rum sporozoite surface antigens was assessed using a previ­
ously described “wet” IFAT on NF54 sporozoites that had
been very lightly glutaraldehyde fixed (0.05 %, 2 min) and 
deposited on slides coated with 50 fxg/ml poly-L-lysine
[29].
2.9 Assessment of the biological effect of Ab: inhibition 
of Spz invasion into human hepatocytes
Ab were tested in triplicate for their capacity to inhibit Spz 
invasion of human hepatocytes using the ILSDA assay 
with P. falciparum liver stage cultures essentially as 
described [45]. Briefly, human hepatocytes were isolated 
from < 1 cm3 liver sections by collagenase (Sigma) perfu­
sion and further purified over a 40% Percoll (Pharmacia) 
gradient. Sections were obtained with informed consent 
from organ donors or from biopsies taken for diagnostic 
purposes. Hepatocyte purity and viability were >95% as 
assessed by trypan blue dye exclusion. Monolayers were 
obtained by seeding 12 X 104 hepatocytes per chamber in 
8-chamber Lab-Tek dishes (Nunc) in William’s E medium 
supplemented with 5% FCS (ATGC, France), 1 X 
penicillin-streptomycin (Gibco BRL), 2 mM glutamine 
(Gibco BRL). After 24 h at 37 °Cin 5 % C 02, the medium 
was removed and test Ab or control reagents were added 
to each chamber. Thereafter, P. falciparum (strain NF54) 
Spz, which had been freshly dissected from infected saliv­
ary glands of Anopheles gambiae, washed and suspended 
in fresh supplemented medium, were added at 6 X 104 spo­
rozoites per Lab-Tek chamber. After 3 h at 37 °C, the 
medium containing Ab and non-invaded Spz was discarded 
and replaced by normal supplemented medium. After 3-5 
days of culture, hepatocytes were fixed in methanol and 
developing liver stages were counted following identifica­
tion by IFAT with the anti-CS mAb NFS1 [46] (IgGl, 
diluted 1 :1000; a kind gift from Yupin Charoenvit).
All test and control Ab assays were performed as triplicate 
cultures and each Lab-Tek dish contained additional 
duplicate control wells without Ab. The percentage of 
inhibition of sporozoite invasion was calculated as follows: 
% inhibition = [1 - (geometric mean no. of infected hepa­
tocytes in control chambers - geometric mean of no. of 
infected hepatocytes in test chambers from that same 
slide) / geometric mean no. of infected hepatocytes in con­
trol chambers)] X 100. All experiments included the anti- 
CS mAb NSF1 as a positive control at 1 j.ig/ml final con­
centration (corresponding to an IFA titer of 105) which, in 
accordance with previous studies [14,17], consistently gave 
90-97% inhibition.
2.10 Statistical methods
All statistical tests were performed on log(e)-transformed 
data. The Pearson test was used to examine the correlation 
between Ab responses and age and between quantitative 
responses to pairs of peptides. The analysis of variance 
(ANOVA) F-test was used to compare mean Ab responses 
between age groups. The %2 test was used to examine the 
relationship between presence or absence of positive 
response to pairs of peptides.
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3 Results
3.1 STARP-specific IgG is present at high frequencies 
and levels in malaria-endemic populations
To determine the prevalence and level of IgG responses to 
the STARP Ag in individuals exposed to R falciparum 
under natural conditions, the STARP peptides RplO-A 
and RplO-Mixo were used in ELISA assays on individual 
sera from two regions, Dons6 and Podor, representing 
nearly opposite ends of the spectrum of malaria trans­
mission in sub-Saharan Africa (100 and 1-5 infectious bites 
per individual per year, respectively). Results indicate the 
presence of B cell epitopes in the STARP RplO region that 
are frequently recognized by P. falciparum, malaria- 
exposed individuals. Indeed, 90 % and 61 % of the individ­
uals spanning all age groups of Donse and Podor, respec­
tively, showed a positive IgG response to epitopes con­
tained in the RplO-A consensus sequence (Fig. 1). Among 
the adults (>: 21 years), prevalence reached 93 % and 82 % 
in the two areas, respectively. When using the STARP 
mixotope RplO-Mixo, which contains over 50000 closely 
related combinatorial RplO repeat sequences, detectable 
STARP-specific IgG responses were slightly less prevalent, 
being found in 88 % and 49 % of the total Donse and 
Podor samples, respectively
To evaluate differences in the levels of IgG specific to the 
various Ag, positive individual responses were classified 
into four strata, i.e. low (1.00-2.49), medium (2.50-4.99), 
high (5.00-9.99), and very high (>10.00) IgG levels 
(Fig. 1). In an interesting contrast to the prevalence data, 
the use of the combinatorial peptide RplO-Mixo detected
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Figure L IgG prevalence data for STARP (RplO-A, RplO-Mixo) 
vs. CS (R32tet32) and LSA-1 (LSA-Rep) Ag in individuals from 
(A) the high-transmission area of Donse (Burkina Faso, n = 73) 
and (B) the low-transmission area of Podor (Northern Senegal, n 
= 106). Individual IgG levels were calculated in AU; AU values 
>  1 were considered indicative of a positive Ab response. The 
overall percentage of positive Ab responses equals the sum of the 
percentage of individuals whose IgG levels fell into one of the 
four strata indicated (1.00-2,49; 2.50-4.99; 5.00-9.99; >10.00). 
The data for the CS and LSA-1 Ag shown in Figs. 1 and 2 are 
reproduced from [37].
STARP-specific IgG at levels higher than those found 
using the single-sequence peptide RplO-A. For example, 
when using the mixotope, IgG levels falling into the high 
stratum (5.00-9.99) were detected in 29 % and 9 % of the 
Donsé and Podor samples, respectively, as compared to 
19% and 5%, respectively, when using RplO-A. Individ­
ual responses to these two STARP peptides were never­
theless highly correlated, both qualitatively (x2 = 25.0 and 
42.6 for the Donsé and Podor sera, respectively; p <  0.001 
for both) and quantitatively (r = 0.84 for Donsé and r — 
0.82 for Podor).
f
In comparison, the prevalence of positive IgG responses to 
the immunodominant regions of the CS and LSA-1 pro­
teins, determined in the same individual sera using 
R32tet32 and LSA-Rep, reached 97 % for both antigens in 
Donsé and 70 % and 77 %, respectively, in Podor. Interes­
tingly, in both regions the levels of STARP-specific IgG were 
very close to those for the CS. These levels were neverthe­
less far below those specific for the LSA-1 Ag (for example, 
25 % of the Podor samples had very high LSA-Rep- 
specific IgG levels (i.e. levels ^10), as compared to 4% 
and 0 % having very high levels of IgG specific for RplO- 
Mixo and R32tet32, respectively).
Age-dependent changes in IgG levels were then examined 
in both the Donsé and Podor population samples, initially 
chosen for their evenly spread age distribution. For both 
populations, a gradual consistent increase in STARP-
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Figure 3. Inhibitory effect of human anti-STARP Ab on P. falci­
parum Spz invasion of human hepatocytes in vitro. The Y-axis 
shows the starting serum used for affinity purification: D2908 = 
Donsé serum No. 2908 (having titers of 12.4 and 16.7 AU of IgG 
specific for RplO-A and RplO-Mixo, respectively); IS-Vol (having 
titers of 2.0 and 1.8 AU of IgG specific for RplO-A and RplO- 
Mixo, respectively); D2945 = Donsé serum No. 2945 (titer of 17.0 
AU of IgG specific for RplO-Mixo); HIS 12 = hyperimmune 
serum No, 12 (from a holoendemic area in the Congo; titers of 8.0 
AU, 9.2 AU and 2.8 AU of IgG specific for RplO-Mixo, 
R323tet32 and MSP-3b, respectively). HIS1 = Congo hyperim­
mune serum No. 1 [titer of 3.6 AU of IgG specific for (NANP)fi]. 
Ab were affinity purified against either the STARP peptides 
RplO-A or RplO-Mixo, the CS recombinant Ag R32tet32 or pep­
tide Ag (NANP)«, or the control asexual blood-stage merozoite 
Ag peptide MSP-3b [47]. All Ab samples were tested in triplicate 
at 2 fig/ml and percentage inhibition was calculated with respect 
to control wells in which no Ab were added, The STARP and CS 
Ab preparations had Spz IFAT titers of 1:100, while the MSP-3b- 
specific Ab had a Spz IFAT titer of < 1:10 (background).
specific IgG levels with age was demonstrated with both 
RplO peptides (Fig. 2). This was also reflected in the sig­
nificant increase in percentage of positive responders to 
STARP in the older age groups (data not shown)* This dif­
fered notably from the younger age groups in Podor (< 10 
years old) where the majority of children (69 % and 90 % 
as measured by RplO-A and RplO-Mixo, respectively) did 
not show a positive Ab response to the STARP Ag. Inter­
estingly, in adults of the high-transmission area and in all 
age groups of the low-transmission area, the levels of IgG 
specific for STARP were similar or greater than those for 
the CS protein. Again, the rise was much less rapid than 
that observed with levels of LSA-1-specific IgG. For all Ag 
tested, the age-dependent increase was statistically signifi­
cant (p < 0 .0 2 , analysis of variance test).
3.2 Human anti-STARP antibodies dramatically reduce 
sporozoite invasion
We have assessed whether STARP-specific Ab present in 
the sera of individuals exposed to R falciparum Spz can 
inhibit invasion of their natural host cell, the human hepa- 
tocyte, using the established ILSDA in vitro assay [45]. 
Using the RP10-A or RplO-Mixo STARP peptides as solid 
phase Ag, human anti-STARP Ab were affinity purified 
from sera of African individuals, exposed to P falciparum 
infection under natural conditions and highly reactive to
STARP peptides (Fig. 3 legend) and, from a volunteer 
experimentally protected against multiple challenges by 
repeated immunization with R falciparum IrrSpz ([4]; D. 
Haynes and W. R. Ballou, unpublished data).
Significant inhibition, measured as a reduction in the num­
ber of resulting P. falciparum liver stages 3-5 days post­
invasion, was consistently found with polyclonal STARP- 
specific human Ab prepared from either African immune 
sera or the IrrSpz-immunized volunteer (IS-Vol) serum 
and tested at a concentration of 2 fxg/ml (Fig. 3). Levels of 
inhibition ranged from 48% to 90% (with a mean of 
64%), depending on the serum and the STARP peptide 
used for affinity purification. No correlation was observed 
for this small number of sera between initial STARP Ab 
titers and levels of Spz inhibition. In contrast, human poly­
clonal anti-CS Ab prepared under exactly the same condi­
tions gave only minimal (13 % ) inhibition when Ab were 
purified against the (NANP)6 peptide, and 43 % inhibition 
when using the R32tet32 recombinant protein (containing 
a greater number of repeats and the variant tetrapeptide 
NVDP) as the solid-phase Ag. Negative control Ab, simi­
larly affinity purified against the asexual blood-stage 
merozoite Ag MSP3 which is not expressed in Spz [47], 
gave no significant inhibition (< 10 %). Using a 24-h assay, 
2 |Ag/ml STARP-specific IgG purified from the D2945 and 
D2908 sera gave inhibition levels of 82% and 70%, 
respectively; this similar reduction in numbers of invaded 
Spz indicates that Ab were operating at the level of Spz 
invasion.
Subsequent experiments were performed to determine if 
this inhibition with anti-STARP Ab was reproducible, 
whether it was concentration dependent and which classes 
of Ig were implicated. These assays, performed with 
human hepatocytes from another donor and new Ab prep­
arations, focused on the African immune serum D2908 
and the IS-Vol serum, which had previously given the 
highest inhibition levels (Fig. 3). Following affinity puri­
fication, STARP-specific Ab were fractionated into either 
IgG or non-IgG by conventional chromatography and 
tested at 2.0, 1.0 and 0,5 [xg/ml concentrations.
The results confirmed the significant inhibitory activity of 
anti-STARP Ab on Spz invasion of human hepatocytes 
and, furthermore, demonstrated that the level of inhibi­
tion was dependent on the concentration of STARP- 
specific Ab (Table 2). For the Donsé serum D2908, 
STARP-specific Ab prepared from unfractionated serum 
was found to inhibit Spz invasion by up to 90 % and 69 % 
when RplO-Mixo and Rpl0-A, respectively, were used as 
the peptides for affinity purification. A significant but 
lower level of inhibition (47-49 %) was obtained with Ab 
prepared from the IgG fraction, whereas little or no inhib­
itory activity was recovered from the non-IgG fraction. 
These results correlated well with the immunofluorescence 
titers of the various Ab samples, with end-point titers of 
1:100 for Ab prepared from whole serum or the IgG frac­
tion, as opposed to an essentially negative titer (< 1 : 10) 
for the non-IgG sample, suggesting that the only signifi­
cant source of inhibitory anti-STARP Ab in this African 
serum was of the IgG class.
Strong inhibition was also observed with anti-STARP Ab 
purified from un fractionated serum of the IrrSpz-
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Table 2. Percentage inhibition of P. falciparum Spz invasion of human hepatocytcs in the presence of human STARP-specific Ab. dose 
dependency and Ig fractionation studies
Starting serum Peptide used 
for affinity 
purification
Fraction tested'0 Spz IFAT titer Percentage inhibitionh)
2,0 jig/ml
D2908 RplO-Mixo whole 1 : 1 0 0 90.4 48.1
D2908 RplO-Mixo IgG 1 : 1 0 0 47.3 44.6
D2908 RplO-Mixo non-lgG < 1 : 10 21.6 8.4
D2908 Rpl0-A whole 1 : 1 0 0 69.2 67.3
D2908 RplO-A IgG 1 : 1 0 0 48.7 35.1___ \
D2908 RplO-A non-lgG < 1 : 10 20.4 0
IS-Vol RplO-Mixo whole 1 : 1 0 0 80.2 71.4
IS-Vol RplO-Mixo IgG < 1 : 10 13.3 18.1
IS-Vo I RplO-Mixo non-lgG 1 : 1 0 0 58.4 28.2
IS-Vol RplO-A whole 1 : 1 0 0 87.8 86.7
IS-Vol RplO-A IgG 1 : 10 6.1 11.4
IS-Vol Rpl0-A non-lgG 1 : 1 0 0 73.5 61.2
HIS1 [(NANP)r NVDP]2 IgG 1 : 1 0 0 56.0 33.7
HIS5 MSP-3b IgG < 1 : 10 22.3 3.1
0.5 |xg/ml
47.3 
27.9
6.7 
52.8 
13.7 
0
47.6
10.3 
28.2 
56.0
5.9
42.3
28.6 
0
a) Affinity purification of specific Ab was performed either using whole serum or serum previously fractionated into IgG and non-lgG. 
The sera employed were: D2908, Donse serum no. 2908; IS-VoI; HIS, hyperimmune African serum.
b) Indicated are the STARP-specific Ab concentrations tested. The percentage inhibition was calculated with respect to the number ot 
intra-hepatocytic forms obtained in the absence of Ab.
c) Ail values marginally lower or equal to 0 were expressed as 0.
Table 3. Inhibitory effect of mouse anti-STARP antisera on P falciparum Spz invasion of human hepatocytes in vitro
IgG preparation^ STARP-specific IgG
levelsb)
IgG test concentration
(mg/ml)
Spz IFAT titerc) % inhibition
GST+STARP/Rep no. 1 17.4 0.1 1 : 1 0 0 0 41.6
GST+STARP/Rep no. 2 24.8 0.1 1 : 1 0 0 0 52.8
GST+STARP/Rep no. 3 17.0 0.05 1 : 200 68.3
GST+STARP/Rep no. 4 8.9 0.05 1 : 200 42.3
GST no. 1 < 1.0 (negative) 0.1 < 1 : 10 0d)
GST no. 2 < 1.0 (negative) 0,05 < 1 : 10 1 1 . 1
pre-immunization < 1.0 (negative) 0.1 < 1 : 10 0
a) From a total of 27 mice immunized with GST+STARP/Rep, the 12 with the highest levels of STARP-specific IgG (as measured by 
ELISA using the RplO-Mixo peptide) were chosen and split into 4 groups of three (No. 1-4). Serum samples taken from each of 
these 12  mice just prior to immunization were pooled for the negative preimmune control. Control GST-specific IgG were prepared 
from two separate groups of six mice immunized with GST alone.
b) For each mouse, STARP-specific IgG levels were calculated as the ratio of absorbances obtained with the post-immune vs. the pre­
immune serum samples in ELISA assays using the peptide RplO-Mixo as coating Ag. Shown above is the geometric mean of these 
levels for each group of mice. Values 1 clearly indicated the presence of STARP-specific IgG.
c) The IFAT Spz titer shown is that of the IgG preparation tested at the above concentration.
d) All values marginally lower or equal to 0 were expressed as 0.
immunized volunteer, reaching 80-88% inhibition with 
the RplO-Mixo- or RplO-A-specific Ab. Moreover, the 
percentage of inhibition remained elevated even at the 
lowest Ab concentrations (0.5 [xg/ml). Surprisingly, such 
significant inhibitory activity was confined, for this experi­
mentally protected individual, to the non-lgG fraction 
(reaching up to 74% efficacy) while the IgG fraction 
showed no effect. In agreement with this finding, elevated 
Spz IFAT titers (1:100) were found in the non-lgG 
STARP-specific Ab preparation, while the titers of the IgG 
samples were essentially negative (<1:10). The finding 
for both sera that inhibitory activities were lower in the 
fractionated versus unfractionated (“whole”) Ig is possibly 
due to partial denaturation of the fractionated Ig recov­
ered from the two-step process of ion-exchange chroma­
tography and elution of affinity-purified Ab.
In this same experiment (Table 2), a 56% inhibition was 
observed with anti-CS IgG that had been affinity purified 
from a peptide containing the two major CS repeat 
sequences. Again, no significant inhibition was observed 
with affinity-purified Ab specific to the asexual blood stage 
merozoite Ag, MSP-3.
3.3 Anti-STARP Ab induced by immunization are also 
inhibitory
To address the question of whether inhibitory Ab could be 
produced by immunization with recombinant STARP pro­
tein, we immunized mice with either the central repetitive 
region of the STARP Ag (encompassing the Mosaic, Rp45 
and RplO repeat sequences) fused to glutathione S-
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Figure 4. Isotype analysis of Ab responses to STARP in the serum of individuals from malaria-endemic areas or a volunteer experimen­
tally immunized with IrrSpz. The arithmetic mean +SEM of the levels of STARP-specific IgG 1-4, IgA or IgM, calculated for the high- 
transmission Dons6 (n — 63) and low-transmission Podor (n = 99) sera samples is shown (left and center panel). Indicated above are the 
percentage of sera samples for which a positive Ab response to STARP was detected for each (sub)class. Note that a positive response 
was defined as one for which the Ab level, as calculated in arbitrary units, was >1.0, Data were retained only from those individuals for 
which all iso type studies were performed. (Right panel): Levels of anti-STARP Ab detected in the serum of an IS-Vol. This indicates 
that the STARP-specific Ab response in this individual was restricted to the IgGl, IgG4, IgA and IgM (sub)classes. Note that for all 
these ELISA assays (performed using the STARP RplO-A peptide as coating Ag), total IgG was measured using 1:100 serum dilutions, 
whereas IgGl-4, IgA and IgM were measured using serum dilutions of 1:25.
transferase (GST+STARP/Rep), or with GST alone. 
ILSDA assays were performed using IgG purified from 
either post-immune or pre-immune sera (Table 3). No 
inhibition was seen either with control IgG from GST- 
immunized mice or IgG prepared from pooled preimmune 
sera from the mice subsequently immunized with recombi­
nant STARP protein. However, purified post-immune 
anti-GSTH-STARP/Rep IgG did reduce Spz invasion of 
hepatocytes by 42-68 % . These data imply that inhibition 
was due to the effect of STARP-specific IgG. Indeed, 
IFAT and ELISA data indicated the presence of significant 
levels of STARP-specific IgG in the post-immune sera of 
GST+STARP/Rep-immunized mice, with Spz IFAT titers 
reaching 1:200 to 1:1000, whereas anti-GST or preim­
mune sera were negative. Interestingly, the highest level of 
inhibition (68 %) was not found with the preparations hav­
ing the highest (1 : 1000) titers, but instead with a 
GST+STARP/Rep IgG preparation that had a Spz IFAT 
titer of 1:200. This would suggest that subtle though func­
tionally important differences in Ab specificity between 
these IgG preparations were responsible for the greater 
efficacy of the IgG from mice with lower STARP-specific 
IgG titers, underlying the possible importance of qualitat­
ive factors (i.e. avidity or fine specificity) in determining 
the biological effect of these Ab.
3.4 Isotype analysis of humoral responses to the STARP 
Ag
In view of the known differences in the biological func­
tions of separate Ab species [48, 49] and their distinct roles 
in defense against malaria [40], we investigated which sub­
classes were involved in STARP-specific Ab responses in 
Donse and Podor. Interestingly, results showed that the 
cytophilic isotypes IgG l and IgG3 clearly predominated in 
both populations (Fig. 4). In the Donse group, the mean 
level of STARP-specific IgG was highest for IgG3, 
whereas the prevalence of positive responses was the 
highest for the IgGl isotype, being detected in 98 % of the
individual sera. This higher prevalence, compared to the 
90% prevalence of IgG responses, is likely related to the 
greater sensitivity of the double sandwich ELISA used 
and/or the lower serum dilution employed for the isotype 
analyses. Sixty-eight percent of the sera also contained 
STARP-specific Ab of the IgG3 and IgG4 isotypes, the lat­
ter in spite of weakly positive levels. STARP-specific IgG2 
was both infrequent and of low levels when detected. 
Surprisingly, STARP-specific Ab of the IgA class were 
encountered in up to 38 % of the sera, although the levels 
were generally very low. IgM responses were detected in 
only 2 2 % of the population sampled, and levels were in 
general even lower than those of IgA.
In Podor, the overall picture of isotype distribution was 
essentially similar to that of Donse, except that the mean 
titers and prevalences were lower (Fig. 4), in agreement 
with the lower exposure to pre-erythrocytic stages in this 
area, with again a net predominance of IgG l and IgG3 
specific for STARP.
Overall, only IgGl and IgG3 showed a statistically signifi­
cant increase in Ab levels with age for both population 
samples. The remarkable dominance of these two isotypes 
was reflected in the finding that there was not a single indi­
vidual from either Donse or Podor that was positive for 
only IgG2 and/or IgG4 (and negative for IgGl and IgG3).
A similar isotype analysis, carried out for the IS-Vol 
serum, revealed unexpected differences. Most notably, 
among the IgG, the response to STARP was restricted 
mainly to IgG4, with a borderline IgG l response and no 
IgG3 or IgG2. Though low, positive levels of STARP- 
specific Ab were also detected within the IgA and IgM 
classes. It was subsequently found that under our experi­
mental conditions the chromatographic separation tech­
nique recovered IgGl-3 in the IgG fraction, while the non- 
lgG fraction was enriched in IgG4 as well as IgA and IgM 
(data not shown). Thus, in the case of the IS-Vol serum, 
the inhibitory effect of affinity-purified STARP-specific 
Ab correlated with the presence of IgG4, IgA and IgM.
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4 Discussion
For many years, Ab responses to Plasmodium Spz and the 
abundant CS surface protein have been considered one 
and the same; indeed, many papers have measured Ab 
responses to Spz on the basis of reactivity to CS repeats, 
and one recent review stated that “all neutralizing antibod­
ies to sporozoites are directed against repeats of the CS 
protein” [50]. Our data challenge this dogma by showing 
that Ab to a recently identified Spz surface protein known 
as STARP [25, 26] are frequently present in naturally 
exposed individuals and attain levels equivalent to those 
found specific for the CS protein. More importantly, 
STARP-specific Ab, affinity purified from the serum of 
individuals either naturally exposed to, or experimentally 
protected against pre-erythrocytic stages of P. falciparum, 
can significantly inhibit P falciparum Spz invasion of 
human hepatocytes. This further demonstrates the surface 
location of the molecule and provides compelling evidence 
that immune responses to this Ag can play a biological role 
in limiting Spz invasion of hepatocytes. We note that there 
is growing evidence from bed-net and other studies that 
reducing the numbers of Spz entering the liver can lead to 
a reduction in parasite density and malaria-associated mor­
bidity and mortality [51; 52 and references within]. Thus, 
elicitation of an Ab response that prevents most although 
perhaps not all Spz from entering the liver, by means of a 
vaccine incorporating STARP, may be of significant help in 
combating malaria.
The target of those neutralizing Ab to STARP, the RplO 
repeat region, is known to be highly conserved in R falci­
parum [25, 26]. Its potent antigenicity is demonstrated by 
the finding that even in a region where transmission levels 
(1-5 infectious bites / individual / year) are amongst the 
lowest of sub-Saharan, malaria-endemic Africa, IgG spe­
cific for the conserved peptide RplO-A was found in 82 % 
of adults. IgG responses to the RplO region were also mea­
sured using a “mixotope” Ag. The mixotope approach, 
based on combinatorial synthesis, represents a novel 
means of simultaneously generating a series of epitope 
motifs represented by a multiplicity of closely related 
sequences. This was initially developed to mimic the 
hypervariable V3 loop of the HIV-1 gp'120 envelope pro­
tein [36]. Remarkably, the FIIV-1 mixotope was able to 
prime an immune response which could be stimulated 
in vitro by a range of polymorphic MHC-restricted V3 
sequences and to elicit Ab, CD4+ and CD8+ responses in 
multiple genetic backgrounds [53]. STARP was chosen as 
a good candidate for further studying the utility of this 
approach since the considerable degeneracy of the RplO 
region had been predicted to result in multiple closely 
related epitopes [25], thus creating a “natural” mixotope. 
Interestingly, when using the combinatorial RplO mixo­
tope, the prevalence of STARP-specific IgG responses was 
only slightly reduced, while the mean levels of Ab detected 
in this way were higher, as compared to the conserved 
single-repeat sequence RplO-A. A likely explanation is 
that the mixotope, which contains many related epitopes, 
is able to recruit an enlarged population of Ab directed to 
the RplO region, while the consensus RplO-A peptide con­
tains the major Bcell epitope(s). Mixotopes may thus be 
more accurate than unique peptides in reflecting the true 
extent of polyclonal specificities to native repeat antigens 
of Plasmodium and provide an interesting alternative both
for immunological studies and research into peptide-based 
vaccines.
To test whether anti-STARP Ab could contribute to 
defense against malaria, we chose the ILSDA assay, which 
uses the natural host cell, i.e. the human hepatocyte [45], 
as opposed to the more frequently used and amenable 
“inhibition of sporozoite invasion” (ISI) assay, which relies 
on the tumoral hepatoma cell line, HepG2-A16 [54]. In 
spite of the logistical complications, several critical differ­
ences make it imperative to use primary human hepato­
cytes to obtain reliable data. In practical terms, the lack of 
P. falciparum development in HepG2 directly influences 
the assessment of results. In our experience, it has proven 
extremely difficult to distinguish between a uninuclear, 
blocked parasite inside a HepG2 cell and a rounded-up 
Spz that is immediately adjacent though still extracellular. 
In contrast, within hepatocytes, the normal development 
of the parasite leads to the production of liver schizonts 
that after 3-5 days are readily distinguishable from non­
invaded Spz by their large size, intrahepatocytic localiza­
tion and morphology Moreover, HepG2 cells clearly differ 
functionally from host hepatocytes, as evidenced by the 
totally artificial receptivity of the former for the rodent 
malaria parasite P, berghei [55], contrasting with its inabil­
ity to permit intrahepatocytic development of P. falcipa­
rum [54]. This demonstrates critical differences which may 
also concern their susceptibility to invasion. Indeed, multi­
ple comparative studies have revealed major discrepancies 
in the inhibitory effect of Ab to Spz molecules, frequently 
being near-total for HepG2 while dramatically weaker for 
hepatocytes [56-59, 14]. Indeed, in one study, Ab found to 
significantly inhibit P. falciparum Spz invasion of HepG2 
cells gave the opposite result, i.e. an increase in the num­
bers of invaded Spz, in human hepatocytes [57]. Further­
more, data from three human vaccine trials show a lack of 
correlation between levels of ISI in HepG2 and protection 
status [4, 60, 61]. In favor of the relevance of the ILSDA 
hepatocyte assay, a close correlation has been observed, 
for both P. falciparum and P. yoelii, between the levels of 
anti-Spz immunity in vivo and the inhibition found with 
the relevant anti-Spz Ab in vitro [15, 17, 18]. These find­
ings lend weight to the assertion that data obtained using 
human hepatocytes will more faithfully reflect the true 
capacity of these Ab to limit Spz invasion in vivo.
Our ILSDA results show that human STARP-specific Ab 
can prevent up to 90 % of P. falciparum Spz from penetrat­
ing human hepatocytes. To our knowledge, this is the first 
demonstration that Ab present in the sera of naturally 
exposed or experimentally protected individuals have 
been affinity purified against a Spz Ag and shown to be so 
effective in reducing hepatocyte invasion. In comparison, 
the relatively few ILSDA results with polyclonal Ab raised 
to other Spz Ag have shown variable or lower inhibition 
(Pfsl6 : 44-67 % inhibition at 1:100 mouse serum dilution 
[58]; TRAP/PfSSP2 : 44-52% inhibition at 1:10-1:20 
mouse serum dilution, no effect at 1:40 dilution, no pre­
bleed control [16]; CS: —109% [Le. facilitation of invasi­
on] to 4% inhibition at 10 [Ag/ml purified human IgG [57]; 
20-90 % inhibition at 1:10 mouse serum dilution [14]). In 
our study only limited (13-43%) inhibition was recorded 
with human polyclonal anti-CS Ab. Inhibition levels with 
anti-STARP Ab were both reproducible and dependent on 
the Ab concentration (tested at 2.0, 1.0 and 0.5 (xg/ml).
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These are below concentrations obtainable in humans 
using highly immunogenic vaccine systems ([62] and refe­
rences therein). Encouragingly, we did not observe a faci­
litation of Spz invasion rates at the lower Ab concentra­
tions as has been reported with the ILSDA assay using Ab 
specific for the P. falciparum or P. yoelii CS protein [57, 
63].
Similarly efficient inhibition was recorded with anti- 
STARP Ab purified from both the IrrSpz volunteer and 
African immune sera. While the former displayed com­
plete protection against multiple Spz challenges (in the 
absence of CTL activity to the CS protein [31]), including 
one made 2 weeks after the serum was drawn, the level of 
pre-erythrocytic stage immunity of the African individuals 
is less defined. Nevertheless, several studies do suggest 
that individuals living in malaria-endemic areas can 
develop fairly effective, though not sterile, biological 
defenses that prevent a high proportion of Spz inocula­
tions from reaching blood-stage infections ([64-66]; P. 
Druilhe, data not published). One could speculate that 
STARP-specific Ab contribute to these individuals’ 
immune status.
We have found that immunization of mice with purified 
recombinant STARP expressed in E. coli led to the synthe­
sis of IgG that recognized the native Ag and gave substan­
tial inhibition (42-68%) in vitro. While we now need to 
assess alternative Ag presentation systems and adjuvants, 
these results are encouraging in light of the experience 
with CS vaccines where it has generally been much more 
difficult to induce Spz-neutralizing Ab than had been anti­
cipated by the results of passive transfer experiments with 
anti-CS mAb (reviewed in [50]).
In view of these results, experiments with anti-STARP Ab 
in Aotus monkeys are being initiated to compare inhibition 
of Spz invasion in vitro with the effect of passive transfer in 
vivo, i.e. to assess the extent to which inhibition in vitro 
translates to efficacy in vivo. These inhibition results also 
warrant further investigations to test whether STARP 
might be a ligand involved in hepatocyte invasion. 
Already, two molecules, CS andTRAP/PfSSP2, have been 
identified as components of the process of hepatocyte rec­
ognition and invasion [67, 68].
Our isotype analyses of the two malaria-endemic popula­
tions revealed that both the prevalence and mean levels of 
IgG l or IgG3 responses to STARP far exceeded those 
seen with the IgG2 or IgG4 isotypes. A similar predomi­
nance of cytophilic IgG has also been observed with 
human Ab responses to the P. falciparum CS, MSP-1 and 
MSP-2 Ag [43, 44, 69]. For STARP, there was also a clear 
age-dependent increase in the ratio of cytophilic to non- 
cytophilic IgG responses. Interestingly, for malaria blood 
stages (as for other parasitic infections [70]), there is 
increasing evidence of the importance of a predominantly 
cytophilic Ab response for protection [42, 71-75] which is 
further strengthened by the apparent relationship between 
a progressive switch to cytophilic IgG and the gradual 
acquisition of protection [40], as well as by the critical role 
assigned to the monocyte-dependent, cytophilic Ab- 
mediated mechanism of ADCC [76]. In the case of immu­
nity to pre-erythrocytic stages, there are data to support 
both direct and cell-mediated effects of Ab, with isotype
distribution potentially being critical for the latter [77, 78], 
Indeed, in P. berghei CS-immunized mice, it was found 
that titers of mouse (cytophilic) IgGl to the Spz surface 
and Ab avidity paralleled acquisition of sterile immunity 
[77]. Also, infected hepatocytes have been found to be 
prone to Kupffer cell-mediated ADCC [78], As a result of 
its expression by intrahepatocytic parasites [25], STARP 
may be a potential target of ADCC. There is, however, no 
evidence to indicate that isotype is important at the level 
of blocking Spz invasion and it is likely that all isotypes 
could be equally effective.
Unexpectedly, the IrrSpz-immunized volunteer’s STARP- 
specific response was composed essentially of IgG4, IgM 
and IgA. This observation has recently been confirmed by 
isotype analyses of four additional volunteers’ sera show­
ing that two had similarly elevated levels of IgM, while 
increased levels of IgG4 and IgG3 were found in one and 
two individuals, respectively. One possible explanation is 
that the predominantly IgM response to STARP in the 
IrrSpz-immunized volunteers may be associated with 
exposure over a relatively short time frame to high Ag 
(Spz) doses, leading to a lack of maturation towards a 
mostly IgG response, while in endemic areas, people are 
exposed over many years to low Spz numbers and IgG 
response develops. Indeed, Spz Ag-specific immune 
responses have been found to differ depending on whether 
the vertebrate host was naturally exposed to malaria para­
sites or immunized with IrrSpz ([79, 80]; P. Druilhe, 
unpublished data). Whether IgM, by nature of its aggluti­
nating ability, was primarily responsible for the powerful 
biological activity of this serum against Spz invasion de­
serves further evaluation.
Previous studies have already indicated that STARP can 
elicit human CTL responses [27, 28], and ongoing studies 
in Africa with human PBMC (L. Ralamboranto et aL, in 
preparation) have shown that STARP peptides can induce 
a high frequency of Tcell proliferative responses and secre­
tion of IFN-y, the cytokine with the most potent effect 
upon liver schizogony [81]. The present study documents 
the antigenicity of this molecule and shows that STARP- 
specific Ab induced by either natural exposure or artificial 
immunization exert a biological role at an essential phase 
of the pre-erythrocytic cycle, i.e. that of host cell invasion. 
The challenge now is to assess the relative importance of 
each STARP-specific immune effector arm in defense 
against parasite challenge. These results validate our 
search for alternative pre-erythrocytic stage molecules [24] 
and provide compelling evidence that STARP may prove 
to be a powerful component in development of a future 
anti-pre-erythrocytic stage malaria vaccine.
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